Go Pro
→ $40,000,000,000,000 (From American Alternative) (Ad)tc pixel Free TLSI Stock Alerts

TriSalus Life Sciences (TLSI) Competitors

TriSalus Life Sciences logo
$5.10 +0.20 (+4.08%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$5.12 +0.02 (+0.29%)
As of 09/18/2026 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TLSI vs. BVS, ENOV, IRMD, CBLL, and NNNN

Should you buy TriSalus Life Sciences stock or one of its competitors? TriSalus Life Sciences's main competitors and comparable companies include Bioventus (BVS), Enovis (ENOV), iRadimed (IRMD), CeriBell (CBLL), and Anbio Biotechnology (NNNN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does TriSalus Life Sciences compare to Bioventus?

TriSalus Life Sciences (NASDAQ:TLSI) and Bioventus (NASDAQ:BVS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

In the previous week, TriSalus Life Sciences had 1 more articles in the media than Bioventus. MarketBeat recorded 1 mentions for TriSalus Life Sciences and 0 mentions for Bioventus. TriSalus Life Sciences' average media sentiment score of 0.52 beat Bioventus' score of 0.00 indicating that TriSalus Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
TriSalus Life Sciences Positive
Bioventus Neutral

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 16.3% of TriSalus Life Sciences shares are owned by company insiders. Comparatively, 33.5% of Bioventus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

TriSalus Life Sciences has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, Bioventus has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

TriSalus Life Sciences presently has a consensus target price of $8.67, indicating a potential upside of 69.93%. Bioventus has a consensus target price of $16.80, indicating a potential upside of 30.13%. Given TriSalus Life Sciences' higher possible upside, equities research analysts clearly believe TriSalus Life Sciences is more favorable than Bioventus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TriSalus Life Sciences
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Bioventus
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

Bioventus has a net margin of 9.36% compared to TriSalus Life Sciences' net margin of -62.59%. Bioventus' return on equity of 28.08% beat TriSalus Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
TriSalus Life Sciences-62.59% N/A -64.47%
Bioventus 9.36%28.08%9.82%

Bioventus has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TriSalus Life Sciences$45.15M6.96-$39.23M-$1.30N/A
Bioventus$568.09M1.91$22.73M$0.7716.77

Summary

Bioventus beats TriSalus Life Sciences on 12 of the 16 factors compared between the two stocks.

How does TriSalus Life Sciences compare to Enovis?

Enovis (NYSE:ENOV) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

In the previous week, Enovis had 11 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 12 mentions for Enovis and 1 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 0.52 beat Enovis' score of 0.28 indicating that TriSalus Life Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enovis
2 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
TriSalus Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Enovis presently has a consensus target price of $40.38, indicating a potential upside of 123.94%. TriSalus Life Sciences has a consensus target price of $8.67, indicating a potential upside of 69.93%. Given Enovis' stronger consensus rating and higher possible upside, equities analysts clearly believe Enovis is more favorable than TriSalus Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enovis
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75
TriSalus Life Sciences
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

98.5% of Enovis shares are held by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are held by institutional investors. 2.9% of Enovis shares are held by company insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Enovis has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Enovis has a net margin of -47.96% compared to TriSalus Life Sciences' net margin of -62.59%. Enovis' return on equity of 12.03% beat TriSalus Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Enovis-47.96% 12.03% 4.91%
TriSalus Life Sciences -62.59%N/A -64.47%

TriSalus Life Sciences has lower revenue, but higher earnings than Enovis. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enovis$2.25B0.46-$1.18B-$19.26N/A
TriSalus Life Sciences$45.15M6.96-$39.23M-$1.30N/A

Summary

Enovis beats TriSalus Life Sciences on 11 of the 16 factors compared between the two stocks.

How does TriSalus Life Sciences compare to iRadimed?

iRadimed (NASDAQ:IRMD) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

In the previous week, TriSalus Life Sciences had 1 more articles in the media than iRadimed. MarketBeat recorded 1 mentions for TriSalus Life Sciences and 0 mentions for iRadimed. TriSalus Life Sciences' average media sentiment score of 0.52 beat iRadimed's score of 0.00 indicating that TriSalus Life Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
iRadimed Neutral
TriSalus Life Sciences Positive

92.3% of iRadimed shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 34.6% of iRadimed shares are owned by insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

iRadimed presently has a consensus target price of $120.00, indicating a potential upside of 46.13%. TriSalus Life Sciences has a consensus target price of $8.67, indicating a potential upside of 69.93%. Given TriSalus Life Sciences' higher possible upside, analysts clearly believe TriSalus Life Sciences is more favorable than iRadimed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iRadimed
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00
TriSalus Life Sciences
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

iRadimed has a net margin of 26.70% compared to TriSalus Life Sciences' net margin of -62.59%. iRadimed's return on equity of 23.45% beat TriSalus Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
iRadimed26.70% 23.45% 20.36%
TriSalus Life Sciences -62.59%N/A -64.47%

iRadimed has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

iRadimed has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iRadimed$83.81M12.53$22.48M$1.7945.88
TriSalus Life Sciences$45.15M6.96-$39.23M-$1.30N/A

Summary

iRadimed beats TriSalus Life Sciences on 13 of the 16 factors compared between the two stocks.

How does TriSalus Life Sciences compare to CeriBell?

TriSalus Life Sciences (NASDAQ:TLSI) and CeriBell (NASDAQ:CBLL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

TriSalus Life Sciences has a net margin of -62.59% compared to CeriBell's net margin of -64.73%. TriSalus Life Sciences' return on equity of 0.00% beat CeriBell's return on equity.

Company Net Margins Return on Equity Return on Assets
TriSalus Life Sciences-62.59% N/A -64.47%
CeriBell -64.73%-44.85%-35.69%

TriSalus Life Sciences has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. Comparatively, CeriBell has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

2.6% of TriSalus Life Sciences shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 17.7% of CeriBell shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, CeriBell had 10 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 11 mentions for CeriBell and 1 mentions for TriSalus Life Sciences. CeriBell's average media sentiment score of 0.56 beat TriSalus Life Sciences' score of 0.52 indicating that CeriBell is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TriSalus Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CeriBell
5 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

TriSalus Life Sciences has higher earnings, but lower revenue than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TriSalus Life Sciences$45.15M6.96-$39.23M-$1.30N/A
CeriBell$89.06M10.50-$53.41M-$1.76N/A

TriSalus Life Sciences currently has a consensus target price of $8.67, suggesting a potential upside of 69.93%. CeriBell has a consensus target price of $24.40, suggesting a potential upside of 0.12%. Given TriSalus Life Sciences' higher probable upside, equities research analysts plainly believe TriSalus Life Sciences is more favorable than CeriBell.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TriSalus Life Sciences
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
CeriBell
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71

Summary

CeriBell beats TriSalus Life Sciences on 10 of the 17 factors compared between the two stocks.

How does TriSalus Life Sciences compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

In the previous week, Anbio Biotechnology and Anbio Biotechnology both had 1 articles in the media. TriSalus Life Sciences' average media sentiment score of 0.52 beat Anbio Biotechnology's score of -0.54 indicating that TriSalus Life Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Anbio Biotechnology
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative
TriSalus Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Anbio Biotechnology has higher earnings, but lower revenue than TriSalus Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anbio Biotechnology$8.65M87.33$6.40MN/AN/A
TriSalus Life Sciences$45.15M6.96-$39.23M-$1.30N/A

TriSalus Life Sciences has a consensus price target of $8.67, indicating a potential upside of 69.93%. Given TriSalus Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe TriSalus Life Sciences is more favorable than Anbio Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anbio Biotechnology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
TriSalus Life Sciences
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

2.6% of TriSalus Life Sciences shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Anbio Biotechnology has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -62.59%.

Company Net Margins Return on Equity Return on Assets
Anbio BiotechnologyN/A N/A N/A
TriSalus Life Sciences -62.59%N/A -64.47%

Anbio Biotechnology has a beta of 5.17, indicating that its stock price is 417% more volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

Summary

TriSalus Life Sciences beats Anbio Biotechnology on 7 of the 12 factors compared between the two stocks.

Get TriSalus Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TLSI vs. The Competition

Export
MetricTriSalus Life SciencesHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$314.03M$5.55B$7.24B$13.19B
Dividend YieldN/A1.80%2.57%12.81%
P/E Ratio-3.9225.34274.9325.38
Price / Sales6.9672.49646.0189.45
Price / CashN/A32.6476.2551.42
Price / Book-7.505.6910.466.33
Net Income-$39.23M$151.55M$3.49B$358.33M
7 Day Performance9.44%0.66%0.59%1.12%
1 Month Performance-2.49%-3.33%-1.74%-2.39%
1 Year Performance4.08%6.79%18.13%5.35%

TriSalus Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TLSI
TriSalus Life Sciences
2.2095 of 5 stars		$5.10
+4.1%		$8.67
+69.9%		+4.1%$314.03M$45.15MN/A102
BVS
Bioventus
3.6365 of 5 stars		$13.56
-1.9%		$16.80
+23.9%		+86.3%$1.14B$568.09M17.611,200
ENOV
Enovis
3.7459 of 5 stars		$18.98
-5.0%		$40.38
+112.7%		-44.3%$1.09B$2.30BN/A7,802
IRMD
iRadimed
2.5717 of 5 stars		$83.53
-1.0%		$120.00
+43.7%		+16.4%$1.07B$83.81M46.66110
CBLL
CeriBell
1.895 of 5 stars		$24.36
+0.2%		$24.40
+0.2%		+98.9%$934.94M$89.06MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TLSI) was last updated on 9/20/2026 by MarketBeat.com Staff.
From Our Partners
$40,000,000,000,000
The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...
American Alternative | Sponsoredtc pixel
“Elon’s nightmare” could fund your retirement
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
You’ve never seen anything like this before
For centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...
Porter & Company | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel